Item 6. EXHIBITS

Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K). The Exhibits designated by the symbol ‡‡ are management contracts or compensatory plans or arrangements.


Exhibit No.						Description
‡‡10a						Bristol-Myers Squibb Company 2026 Stock Award and Incentive Plan (incorporated herein by reference to Exhibit B to Bristol-Myers Squibb Company’s Definitive Proxy Statement filed on March 25, 2026).
22						Sub sidiary Issu ers of Guarantee Securities (incorporated by reference to Exhibit 22 of Bristol Myers Squibb Company's Annual Report on Form 10-K filed on February 11, 2026)
31a.						Section 302 Certification Letter (filed herewith).
31b.						Section 302 Certification Letter (filed herewith).
32a.						Section 906 Certification Letter (furnished herewith).
32b.						Section 906 Certification Letter (furnished herewith).
101.INS						Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						Inline XBRL Taxonomy Extension Schema Document.
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Keytruda and Winrevair are trademarks of Merck & Co., Inc., Rahway, NJ, USA; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.

SUMMARY OF ABBREVIATED TERMS

Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:


2025 Form 10-K	Annual Report on Form 10-K for the fiscal year ended December 31, 2025	Merck	Merck & Co., Inc., Rahway, NJ, USA
2seventy bio	2seventy bio, Inc.	MF	myelofibrosis
ANDA	Abbreviated New Drug Application	Mirati	Mirati Therapeutics, Inc.
AstraZeneca	AstraZeneca PLC	MZL	marginal zone lymphoma
AOCL	Accumulated other comprehensive loss	NDA	New Drug Application
BioArctic	BioArctic AB	NHL	Non-Hodgkin's Lymphoma
BioNTech	BioNTech SE	oHCM	Obstructive Hypertrophic Cardiomyopathy
Celgene	Celgene Corporation	Ono	Ono Pharmaceutical Co., Ltd
CERCLA	U.S. Comprehensive Environmental Response, Compensation and Liability Act	PD-1	programmed cell death protein 1
cHL	classical Hodgkins Lymphoma	PD-L1	programmed death-ligand 1
CRC	colorectal cancer	PDUFA	Prescription Drug User Fee Act
CVR	Contingent value right	Pfizer	Pfizer, Inc.
Dr. Reddy's Laboratories	Dr. Reddy’s Laboratories, Limited and Dr. Reddy’s Laboratories, Inc.	PFS	progression-free survival
EC	European Commission	PsA	psoriatic arthritis
EPS	earnings per share	Quarterly Report on Form 10-Q	Quarterly Report on Form 10-Q for the quarter ended June 30, 2026
ESCC	esophageal squamous cell carcinoma	R&D	research and development
EU	European Union	RDFV	readily determinable fair values
Evotec	Evotec SE	REMS	risk evaluation and mitigation strategy
Exchange Act	the Securities Exchange Act of 1934	Roche	F. Hoffman-La Roche & Co.
FASB	Financial Accounting Standards Board	RRMM	relapsed or refractory multiple myeloma
FDA	U.S. Food and Drug Administration	Sanofi	Sanofi S.A.
GAAP	generally accepted accounting principles	SAR	Special Administrative Region
GTN	gross-to-net	SEC	U.S. Securities and Exchange Commission
HCM	hypertrophic cardiomyopathy	sNDA	supplemental New Drug Application
Hengrui	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	SPC	Supplementary Protection Certificate
HHS	Health and Human Services	SystImmune	SystImmune, Inc.
IPRD	in-process research and development	TNBC	triple negative breast cancer
IRA	Inflation Reduction Act of 2022	UK	United Kingdom
IRS	Internal Revenue Service	U.S.	United States
IT	Information Technology	VAT	value added tax
MCL	mantle cell lymphoma	VEGF-A	Vascular endothelial growth factor A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT)

Date:	July 30, 2026	By:	/s/ Christopher Boerner, Ph.D.
			Christopher Boerner, Ph.D. Chair of the Board and Chief Executive Officer

Date:	July 30, 2026	By:	/s/ David V. Elkins
			David V. Elkins Chief Financial Officer

Previous: Item 5. OTHER INFORMATION